Background: Recent genome-wide expression studies suggest that ϳ80% of the human 25 000 genes undergo alternative splicing. Alternative splicing may be associated with human diseases, and particularly with cancer, but the molecular disease mechanisms are poorly understood. Convenient, novel methods for multiplexed detection of alternatively spliced transcripts are needed. Methods: We devised a new approach for detecting splice variants based on a tag-microarray minisequencing system, originally developed for genotyping single nucleotide polymorphisms. We established the system for multiplexed detection of 61 alternatively spliced transcripts in a panel of 19 cancer-related genes and used it to dissect the splicing patterns in cancer and endothelial cells. Results: Our microarray system detected 82% of the splice variants screened for, including both simple and complex splice variants, in at least 1 of the leukemia cell types analyzed. The intraassay CV-values for our method ranged from 0.01 to 0.34 (mean0.13) for 5 replicate measurements. Our system allowed semiquantitative comparison of the splicing patterns between the cell lines. Similar, but not identical, patterns of alternative splicing were observed among the leukemia cell lines. Size analysis of the PCR products subjected to the tag-array minisequencing system and real-time PCR with exon-junction probes verified the results from the microarray system. Conclusions: The microarray-based method is a robust and easily accessible tool for parallel detection of alter-
The nucleotide sequence of the human genome (1, 2 ) and recent from large scale sequencing of expressed mammalian sequences (3 ) have revealed the unexpected fact that the human genome contains Ͻ25 000 protein-coding genes. In humans, as well as in other eukaryotic organisms, the diversity of the proteome is, to a large extent, created by alternative splicing of pre-mRNAs expressed from individual genes. Using in silico alignment of expressed sequence tags to the genomic sequence, researchers have estimated that 40% to 60% of the mRNAs transcribed from human genes undergo alternative splicing (4, 5 ) . The frequencies of alternative splicing of human genes were estimated in experiments to be 74% in a genome-wide survey of mRNA from multiple tissues using hybridization microarrays with more than 10 000 exon-junction probes (6 ) . According to a study that used Affymetrix GeneChip ® microarrays with closely spaced probes (7 ), over 80% of the genes on chromosomes 21 and 22 appeared to undergo alternative splicing.
The most common forms of alternative splicing of mRNAs are the exclusion or inclusion of a complete exon, mutually exclusive splicing by selection of 1 exon variant, and the use of alternative 5Ј-or 3Ј-splice sites (8 ) . Based on bioinformatics methods, the majority of the alternative splicing events may lead to changes in the protein product (4, 5 ) . On the protein level, alternatively spliced mRNAs may lead to the use of alternative translation initiation sites, or altered translation termination attributable to frame shifts, or the creation or removal of a stop codon, thus causing truncation or extension of the protein product (9 ) .
For most genes, the functional significance of alternative splicing is poorly understood. Alternative splicing may be most important in complex systems where the genetic information must be processed differently at different times, for example in the immune system or during different developmental stages where a very high degreeof diversity is required, such as in the nervous system (5, 8, 10 ) . Many genes that have multiple alternative splice variants, such as receptors and transcription factors, are involved in cell signaling and regulation of gene expression (9 ) . An early study suggests that point mutations causing alternative splicing would be involved in 15% of the inherited diseases (11 ) , and later alternative splicing has been associated with a variety of diseases (12, 13 ) . The most well-known forms of disease-related splicing defects are point mutations in genomic splice sites, exemplified by a mutation causing missplicing of exon 18 in the breast cancer gene, BRCA1 (14 ) . Alternative splicing occurs frequently in human cancer cells (15, 16 ) , and alternatively spliced tumor-specific transcripts might serve as diagnostic markers for cancer (17 ) .
To increase our understanding of the relationship between alternative splicing and human disease, methods are required that allow detection of alternatively spliced mRNAs in a large number of clinically relevant tissue samples and in multiple genes. Highly multiplexed analyses using oligonucleotide microarrays are useful for genomic-scale surveys of alternative splicing, but the costs involved in these methods prohibit their application to large quantities of samples. The most commonly used method for detecting alternatively spliced transcripts in large sample sets are reverse transcription-PCR, followed by size analysis of the PCR products, or real-time PCR using PCR primers that span the splice junctions of the genes of interest (18, 19 ) . A limitation of the PCR-based methods is that they are difficult to multiplex for parallel detection of alternative transcripts from multiple genes.
In this study, we demonstrate that the minisequencingbased tag-microarray system routinely used in our laboratory for multiplexed genotyping of single nucleotide polymorphisms (20, 21 ) can be adapted to multiplex detection of alternatively spliced transcripts. We applied the system to screen for several different types of alternatively spliced transcripts in a panel of 19 cancer-related genes in human leukemia cell lines and in normal endothelial cell lines.
Materials and Methods cell samples
The following cell lines were analyzed: BSM, HL-60, K-562, NB-4, SD-1, HAEC, 1 and HUVEC. SD-1 and BSM are human B-lymphoblastoid cell lines. SD-1 carries the minor breakpoint Philadelphia chromosome. HL-60 is a human acute leukemia cell line from a patient carrying the amplified MYC [v-myc myelocytomatosis viral oncogene homolog (avian)] gene. K-562 is a human chronic myeloid leukemia cell line from a patient carrying the major breakpoint Philadelphia chromosome. NB-4 is a human acute promyelotic leukemia cell line from a patient carrying the PML-RARA fusion gene. SD-1, HL-60, and BSM have been isolated from peripheral blood, while K-562 and NB-4 have been isolated from the bone marrow of the patients. The cell lines HL-60, BSM, and K-562, were a gift from G. Barbany (Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden). The cell lines SD-1 and NB-4 were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany).
The cells were grown in RPMI medium 1640 with 10% fetal bovine serum. HAEC and HUVEC (Cascade Biologics, Inc.) were grown in medium 200 with Low Serum Growth Supplement (LSGS Kit, Cascade Biologics, Inc.). All cell lines were grown at 37°C in a humidified atmosphere of 5% CO 2. Passage 3-5 of the cultures was harvested at 80% confluence according to the manufacturer's instructions.
RNA isolation
Total RNA was isolated from the cells by lysis in guanidine isothiocyanate (TRIZOL ® Reagent, Gibco BRL), and the RNA samples were preserved at Ϫ70°C until use. The purity and integrity of the RNA preparations were assessed by measuring their ultraviolet absorbance at 260 nm and 280 nm and by assaying the RNA with the Agilent 2100 Bioanalyzer (Agilent Technologies). Highquality RNA with an A260/A280 ratio above 1.9 and intact ribosomal 28S and 18S RNA were used for the microarray experiments.
assay design
We included 19 genes, with altogether 61 known alternatively spliced transcripts, in the assay panel (See Table S1 in the Supplemental that accompanies the online version of this article at http://www.clinchem.org/ content/vol52/issue2). The genes and their splice variants were identified in the database Atlas of Genetics and Cytogenetics in Oncology and Hematology (http://www. infobiogen.fr/services/chromcancer). Genes were selected from those with more than one transcript, according to the Ensembl Human Build release, v.24.34e.1 and v.25.34e.1 (http://www.ensembl.org) or according to the NCBI Entrez/Genbank (http://www.ncbi.nlm.nih.gov/entrez). The selected genes are expressed in bone marrow or peripheral blood, according to the GeneCards resource (http://www.dkfz-heidelberg.de/GeneCards/cgi-bin) or according to the literature.
The PCR primers were designed using the Primer3 software (http://www-genome.wi.mit.edu/cgi-bin/primer/ primer3_www.cgi), with the goal to use as few PCR primers per gene as possible. Altogether, 42 PCR primers pairs were required for the amplification of the 61 splice variants of all genes. The PCR products spanning the fragment of interest were analyzed with the BLASTn program (http://www.ncbi.nlm.nih.gov/BLAST) to ensure a specific hit to the human genome sequence. Table S1 (in the online Supplemental Data) shows the expected size of the PCR products.
We designed 43 minisequencing primers, annealing immediately adjacent to nucleotides that define the 61 splice variants of the 19 selected genes (See Table S2 , in the online Supplemental Data). The 5Ј end of each minisequencing primer contained a 20-nucleotide tagsequence from the Affymetrix GeneChip ® Tag Collection. Absence of hairpin loop formation in the minisequencing primers was confirmed using the Cybergene software (http://www.cybergene.se/primer.html). The oligonucleotides were synthesized by Integrated DNA Technologies. The PCR and minisequencing primer sequences are available from the authors upon request.
first-strand cDNA synthesis and PCR The RNA samples were treated with 1 unit RQ1 RNasefree DNase (Promega Corporation) per microgram of total RNA before reverse transcription. An aliquot of 3 g of total RNA was used for first-strand cDNA synthesis in a total reaction volume of 20 L, using the Superscript II reverse-transcription assay (Gibco BRL) according to the manufacturer's protocol. The quality of the cDNA was evaluated on a 1% agarose gel. We used 1 L of a cDNA synthesis reaction mixture as template in PCR with 0.2 mol/L of each amplification primer and 1 L AccuPrime™ Taq DNA polymerase in 25 L AccuPrime™ PCR Buffer 1 (Invitrogen Corporation). The PCR reactions were performed in a PTC225 Thermal Cycler (MJ Research), starting with a 3-min activation of the enzyme at 94°C, followed by 40 amplification cycles of 94°C for 30 s, 55°C for 30 s, and 68°C for 45 s, and a final extension at 72°C for 7 min. Each alternatively spliced transcript was amplified in an individual PCR reaction. All PCR products from the same cell line sample were pooled and concentrated using a Microcon ® YM-30 Centrifugal Filer Devices (Millipore Corporation). The correct size of the PCR products was verified using an Agilent 2100 Bioanalyzer and the DNA 1000 LabChips (Agilent Technologies).
preparation of microarrays
The complementary tag-oligonucleotides were covalently coupled to CodeLink™ Activated Slides (Amersham Biosciences) by the mediation of a NH 2 -group at their 3Ј end. The oligonucleotides were printed in duplicate onto the slides at a concentration of 25 mol/L in 150 mmol/L sodium phosphate pH 8.5, using a ProSys 5510A instrument (Cartesian Technologies Inc.) with 4 Stealth Micro Spotting Pins (TeleChem International Inc.) as previously described (21 ) . The oligonucleotides were printed on the microscope slides in an "array of arrays" format that allowed the parallel analysis of up to 80 individual samples on each microscope slide (22 ) . In each "subarray", a fluorophore-labeled oligonucleotide was included as a printing control. A reference oligonucleotide, complementary to a synthetic template included in the primer extension reaction mixtures to monitor the difference in incorporation efficiency between the 4 nucleotides by the DNA polymerase, was also included in each subarray. Finally, an oligonucleotide designed not to hybridize to any of the oligonucleotides present in the reaction mixture was included in each subarray to be used for background corrections. After printing, the slides were treated with ethanolamine and stored desiccated, in the dark, until use (20 ) . minisequencing A 7-L aliquot of the concentrated PCR products was treated with 5 units of Exonuclease I and 1 unit of shrimp alkaline phosphatase (USB Corporation) to remove excess of PCR primers and dNTPs. The cyclic minisequencing reactions contained the 45 tagged minisequencing primers at 10 nmol/L concentrations, 0.1 mol/L Texas RedddATP, Tamra-ddCTP, and R110-ddGTP, 0.2 mol/L Cy5-ddUTP (Perkin-Elmer Life Sciences) and 0.064 units/l of KlenThermase™ DNA polymerase (GeneCraft). The minisequencing primer extension reactions were performed for 55 cycles of 95°C and 55°C, for 20 s each. The arrayed slides carrying the captured complementary tag-oligonucleotides were preheated to 42°C in a custom-made aluminum reaction rack with a silicon rubber grid forming 80 separate reaction wells on each slide (22 ) . The minisequencing reaction products were added to each well on the slide, and allowed to hybridize to the complementary tag-oligonucleotides at 42°C for 2.0 h to 2.5 h, followed by washing of the slide.
data analysis
The fluorescence signals were measured from the microarray slides using a ScanArray ® Express instrument (Perkin-Elmer Life Sciences), and the signal intensities were determined with the QuantArray ® analysis 3.1 software (Perkin-Elmer Life). The signals from the 4 different fluorophores were normalized by adjusting the laser power of the array scanner to give equal signals for the reference oligonucleotides in 1 subarray. The splice variants of each gene were detected based on the signal-tonoise ratios between the mean value of the fluorescence signals from each nucleotide expected to be incorporated, divided by the mean value of the background fluorescence of the respective nucleotide from the spot containing the oligonucleotide, to which no extension primer was expected to hybridize.
real-time PCR
PCR primers and dual-labeled TaqMan hybridization probes were designed for 9 of the genes using the Primer3 software (http://www-genome.wi.mit.edu/cgi-bin/primer/ primer3_www.cgi). Where possible, the TaqMan probes were designed to flank the exon junctions of the tranClinical Chemistry 52, No. 2, 2006 scripts, but in some cases exon-specific probes were designed. The 5Ј ends of the probes for the 2 transcripts of a gene were labeled with either the fluorophore 6-Fam or Hex, and the 3Ј ends were labeled with Tamra, as a quenching dye. A total of 28 PCR primers were purchased from Integrated DNA Technologies, and 19 labeled TaqMan probes were purchased from Thermo Electron Corporation. Real-time PCR was run using 0.2 mol/L of each amplification primer and labeled probe and 1 L of the 20-L cDNA synthesis reaction product in 25 L of TaqMan Universal PCR Mastermix (Applied Biosystems), containing Rox as a reference dye. The PCR conditions were initial activation of the enzyme at 95°C for 10 min, followed by 45 cycles of 95°C for 15 s, 54°C for 19 s, and 60°C for 1 min in a Stratagene Mx3000P instrument. The signals for the 6-Fam and Hex fluorophores were corrected for the fluorescence of the Rox-labeled reference fluorophore, and Ct-values, which correspond to the first PCR cycle at which a fluorescent signal is detectable, were recorded during PCR. Transcripts that yielded Ct-values Ͻ44 were considered to be present in a cell line.
Results

experimental design
We established a 4-color microarray-based minisequencing system for multiplexed screening for alternatively spliced transcripts. To demonstrate the feasibility of the method, we applied it to 19 genes with 2 to 7 known alternatively spliced transcripts per gene. The genes included are listed in Fig. 1 , and the alternatively spliced transcripts screened for are detailed in Table S1 (in the online Supplemental Data). The majority of the selected genes are involved in hematopoiesis. Several of them are oncogenes, such as the BCL2, MYB, EVI1, TCL1B, and RUNX1 genes. Chromosomal translocations involving RUNX1 are well documented and have been associated with several types of leukemia (23 ) . Another of the genes, WT1, encodes a transcription factor that can activate the protooncogene MYC. Genes for kinases and kinase inhibitors, such as the CDKN2B, DOK1, KITLG, MAP4K4, NPM1, and PTK2B genes are also included in the panel. Using the tag-array minisequencing system, we screened for 61 possible alternatively spliced transcripts of these 19 genes in 5 leukemia cell lines and in 2 endothelial cell lines.
Our strategy for detecting the splice variants expressed from the genes is based on the extension of gene-specific minisequencing primers with fluorescent ddNTPs, each of which define a specific splice variant (See Table S2 , in the online Supplemental Data). For most genes, minisequencing primers that anneal immediately adjacent to a splice junction were used, followed by extension of the primer with fluorescently labeled nucleotides that define the alternatively spliced transcripts, as exemplified in Fig. 2A for the NPM1 gene. In this gene, extension of the primer that anneals to the 3Ј-nucleotides of exon 1 with a fluorescently labeled ddA defines the presence of exon 2, and extension of the primer with a labeled ddG defines the presence of exon 3. The same design was used for splice variants caused by alternative 5Ј-or 3Ј-splice sites. In those genes where the first nucleotide position after a splice junction was identical in 2 alternatively spliced variants, the minisequencing primer was designed to anneal 1 or more nucleotides beyond the splice junction, adjacent to the first nucleotide that differs between the splice variants. For the BCL2L11 gene, 3 splice variants were detected using a single minisequencing primer, but most genes with multiple alternatively spliced transcripts required more than 1 minisequencing primer. For example, the MAP4K gene, in which 4 alternatively spliced variants were identified, required 1 minisequencing primer to define the exon that supersedes exon 15 in 2 of the alternative transcripts. A second minisequencing primer defines the presence or absence of exon 17 in transcripts containing exon 16 (Fig. 2B) . WT1 is the only one of the selected genes with a splicing pattern that can be only partly defined by our system. In WT1, 2 primers define 2 exons, spaced far apart, that might be deleted in different transcripts. Extension of one of the primers with either ddA or ddC defines the presence or absence of exon 5, and the extension of a second primer with ddA or ddG depends on the presence or absence of an additional sequence at the end of exon 9. Although we can detect the presence or absence of different exons, we do not know which of the exons are present on the same transcript Each minisequencing primer contains a unique tagsequence in its 5Ј end that allows the extension products to be captured at a specified position on the microarray surface (Fig. 2C) . Thus a 4-color fluorescence signal pattern will be generated on the microarray to detect each of the 61 alternatively spliced variants. Fig. 2D shows the 4 color fluorescence pattern from the extended primers in the K-562 cell line in one of the subarrays.
detection of alternatively spliced transcripts
We screened 5 leukemia cell lines, HL-60, BSM, NB-4, K-562, and SD-1, and 2 endothelial cell lines, HAEC and HUVEC, for the 61 detectable splice variants in 5 parallel reactions on the same microarray slide. Table S2 (in the online Supplemental Data) exemplifies the numeric fluorescence and CV-values measured from the microarray from the HL-60 cell line, and it illustrates the interpreta- The splice variants are listed from a to g, with a as the longest transcript, followed by the other transcripts in decreasing size. tion of the result based on the signal-to-noise (s/n) ratios obtained after scanning the microarray at 4 wavelengths and after careful normalization of the power of the 4 lasers, using the reaction control signals. The s/n ratios were calculated by dividing the mean value of the expected signal from a primer extension reaction that defines a splice variant with the mean background fluorescence value from the negative control spot for the appropriate fluorophore. We used a conservative detection limit based on a s/n ratio Ͼ10 to be confident that all the detected splice variants were real and not the result of signals from a possible small sequence-dependent misincorporation of labeled ddNTPs by the DNA polymerase that might occur for some variants. Table S3 (in the online Supplemental Data) provides the s/n ratios measured for the splice variants in each of the 19 genes in the cell lines. According to the applied criterion of s/n ratios Ͼ10, 50 of the possible 61 splice variants (82%) were detected in at least 1 the cancer cell lines. In the endothelial cell lines, the number of detected alternatively spliced transcripts was lower, 31 (51%), presumably because the cancer-related genes are not expressed or are expressed at a lower concentration in the endothelial cell lines.
We also calculated a signal fraction (s/f) value that describes the fraction of the total signal contributed by each detectable splice variant to the total signal from all detected splice variants of a particular gene. It should be noted that the incorporation efficiency between the 4 labeled ddNTPs in the primer extension reaction may differ in a sequence dependent fashion, despite normalization of the laser power. Therefore, the s/f values do not provide an accurate measure of the actual abundance of each splice variant, but they do facilitate comparison of the splicing pattern between the cell lines. For some of the genes, the s/f values revealed differences in the splicing pattern between the cell lines. For example, the only transcript of RUNX1 detected in the endothelial cell lines is the b-variant, and the leukemia cell lines express all the transcripts except the c-variant. The RUNX1 c-variant is only detected in the BSM and SD-1 cells, both of which are B lyphoblastoid cell lines. Similarly, the splicing pattern of the RUNX1T1 gene in the BSM and SD-1 cells differs from that in the 3 other leukemia cell lines. The PTK2B c-variant was clearly expressed in the cancer cell lines and absent in the endothelial cells. The CDKN2B a-variant is the dom- To validate our results, we compared the splice variants detected in the microarray analysis from the 7 cell lines with the size of the PCR products originally subjected to minisequencing primer extension using the Bioanalyzer instrument (Table 1) . For 385 (90%) of the 427 alternatively spliced transcripts screened for by the minisequencing system, the size analysis verified our results, either positive or negative. A PCR product corresponding to the expected size was clearly detectable for 266 of the 291 (91%) splice variants detected by the microarray analysis, and 119 of the undetectable splice variants had no visible PCR product of the expected size. A PCR fragment of the expected size was observed as a very weak band for 17 of the possible splice variants that remained undetected by the microarray analysis, while the microarray system detected 25 additional alternative transcripts, most likely reflecting a higher sensitivity of detection of the microarray system. Finally, to validate the results from the minisequencing analysis (Table 2) , we used real-time PCR using TaqMan probes for 9 randomly selected genes with simple splicing patterns. With one exception, all 95 of the splice variants that were detected by the TaqMan probes were also detected by the microarray system, and 84% of the transcripts detected by the minisequencing system were detected using real-time PCR. The transcripts that remained undetected by the TaqMan probes had low signals on the microarray, which implies that they were expressed at low concentrations in these cells.
Discussion
In this study, we show that the tag-microarray minisequencing system originally developed for multiplexed genotyping single nucleotide polymorphisms (20, 21 ) can be adapted for multiplexed detection of alternatively spliced transcripts. The system can be designed and used in parallel for a variety of different types of splice variants. Here we established it successfully both for detecting simple splice variants formed by exclusion or inclusion of complete exons or by alternative usage of 5Ј-or 3Ј-splice sites and for detecting splice variants formed by complex combinations of multiple exonic fragments. The specificity of detecting splice variants based on the sequence specificity of the primer extension reac- tion catalyzed by the DNA polymerase enzyme was verified by size analysis of the PCR-fragments subjected to the reaction and by real-time PCR analysis using exon-junction specific probes for the alternatively spliced transcript of a subset of the genes included in our study. A requirement for designing the primers for our system is that the nucleotide sequences of the alternatively spliced transcripts to be detected are known in advance. This is a declining limitation, as it can be expected that the amount of sequence data on tissue-specific and disease-specific splicing patterns available in public databases will increase rapidly as a result of on-going systematic surveys of alternative splicing using expression profiling by hybridization microarrays on a genome-wide scale (6, 7 ) . A major difference between our minisequencing microarray strategy for detection of splice variants and hybridization using oligonucleotide microarrays is that our system is based on PCR. An obvious advantage of using PCR is the possibility of detecting splice variants that are present at very low abundance in an RNA sample. A limitation shared by all PCR-based methods, compared with well designed hybridization microarrays (24 ) , is that determination of the relative abundance of the splice variants of a gene that are present in a sample is only semiquantitative. The reason for this limitation is that the efficiency of the PCR amplification depends on the sequence of the PCR primers and on the size and sequence of the amplicons. For detecting alternative transcripts the sequence and/or the size of the amplicons, or alternatively, the sequence of at least one of the PCR primers for each transcript differ by necessity. Thus, in PCR-based methods, the measured signals reflect the relative amount of PCR product corresponding to each splice variant, rather than the relative abundance of the alternatively spliced transcripts from each gene in the original sample. Accurate quantification of the original amount of each splice variant would require a competitive PCR strategy, with a standard that is highly similar to each alternative splice variant. Recently, a primer extension strategy similar to ours, for detecting alternative splice variants, was described (25 ) . This system is also based on PCR, followed by primer extension, but uses detection of the primer extension products by mass spectrometry instead of fluorescence, as in our method. Analogous to our method, quantitative determination of the relative amount of alternatively spliced transcripts in the original sample is hampered by differences in PCRefficiency between amplicons of different size, although this limitation does not appear to be recognized in the study. However, as shown by the data in Table S3 (in the online Supplemental Data) and Fig. 3 , our system allows comparison of the relative abundance of the splice variants from each gene between the cell samples. Thus, our PCR-based system may be used for sensitive monitoring of changes in the relative abundance of alternatively spliced transcripts-for example, in serially collected samples or between tissues.
Real-time PCR with hybridization probes targeted at the splice junctions is the most frequently used method for detection of alternatively spliced transcripts at present (19, 26, 27 ) . Also, in real-time PCR, accurate quantitative analysis requires a standard sequence to correct for sequence-dependent differences in PCR-efficiency (18, 19, 28 ) . Compared with real-time PCR, an advantage of our microarray-based system is that multiple splice variants can be analyzed in parallel to generate splicing patterns of multiple genes, while real-time PCR is difficult to multiplex. Another drawback in real-time PCR, as well as other hybridizationbased methods (24 ) ), is that a unique probe is required for each splice variant under study, compared with a system based on primer extension, where the same primer can be used to define alternative transcripts of the same gene. Yet another advantage of our microarray-based system is its "array-of-arrays" format, which facilitates detection of up to 200 primer extension products in 80 samples on each microarray slide (21 ) , in contrast to conventional microarrays for expression profiling, where currently a single sample is analyzed per microarray.
A method based on invasive cleavage of RNA (the Invader Assay) avoids a PCR step and may therefore be potentially more accurate for determining the relative abundance of alternative transcripts than the PCR-based methods (29 ) . However, sequence-dependent factors may affect the efficiency of the consecutive, linear, invasive cleavage reactions used for signal amplification in this method. An interesting method for multiplexed analysis of alternative transcripts is to allow 2 oligonucleotides that flank the splice junctions in each splice variant to hybridize to the RNA targets, followed by ligation of the probes, amplification with the aid of universal PCR primers sequences, capture of the products on beads-arrays using sequence-specific oligonucleotide tags, and detection by a label on one of the PCR primers (30 ) . Another interesting approach describes the use of polymerase colony technology to detect alternatively spliced transcripts using fluorescently labeled exon specific hybridization probes (31 ) , or by detecting exon-specific single nucleotides by minisequencing (32 ) . The "polony" technology permits amplification of individual nucleic acid molecule embedded in an acrylamide matrix. As each polony originates from a single cDNA molecule, the relative amounts of each splice variant can be determined by counting the polonies corresponding to each splice variant. This method combines the high sensitivity of PCR with the possibility of quantitative analysis of the alternatively spliced transcripts. The novel technologies described above rely on equipment and reagents that are not generally available and thus have not yet gained widespread use.
Recent systematic studies using both bioinformatics and experimental approaches imply that many genes display different patterns of alternative splicing in cancer tissues and in normal tissues (8, 26 tial to serve as markers of cancer progression and for follow-up of treatment with anticancer drugs (33 ) . In this study, we used a panel of 19 genes, which may be involved in leukemia in different ways, as a model system for developing a microarray-based minisequencing system for detecting alternatively spliced transcripts. We show that the system can be designed for detecting both simple and complex patterns of alternative splicing and for monitoring changes in the splicing patterns of multiple genes. Based on our results, we conclude that our system is a robust and easily accessible alternative for studying the role of alternative splicing in cancer progression and for sensitive follow-up of the consequences of drug treatment. The format of our assay is also well suited for clinical diagnostics, when, typically, a limited set of biomarkers are analyzed in many samples in each series.
